• Shionogi will present new cefiderocol data at IDWeek 2026 showing better clinical outcomes with early treatment of resistant respiratory infections.
• The U.S. observational analysis of 266 patients linked earlier treatment to higher clinical response than use following failure of another antibiotic regimen.
• Separate surveillance findings showed cefiderocol retained laboratory activity against highly resistant Pseudomonas aeruginosa isolates from patients with ventilator-associated pneumonia.
• A systematic review also found favorable outcomes with cefiderocol in Stenotrophomonas maltophilia infections, though clinical evidence remains limited.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shionogi & Co. Ltd. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210800BIZWIRE_USPR_____20261021_BW236812) on October 21, 2026, and is solely responsible for the information contained therein.